

### 2007: Year of Transformation

Akzo Nobel's Analyst Meeting London and New York



#### Agenda



- 1. Track record
- 2. Strategic rationale for ICI transaction
- 3. Key elements of ICI transaction
- 4. Akzo Nobel going forward
- 5. New financial strategy
- 6. Summary



# TRACK RECORD



### Agenda 2003-2006 – delivering on our promises

- ✓ Fixed pharma
- ✓ Improved operational results
- ✓ Created leadership position in CSR
- ✓ Bolt-on acquisitions
- ✓ Total Shareholder Return of 270% from 2003-2007
- ✓ Improved capital structure



### Chemicals turned into a highly profitable portfolio

- ✓ Restructured portfolio
- ✓ Created five growth platforms
- ✓ Delivered on cost saving programs
- ✓ Operational performance amongst best in class



Significantly improved ROI and EBITDA margin



#### 2007 Deliverables



- ✓ Divestment of Organon BioSciences for €11 billion
- ✓ Offer for ICI including on-sale to Henkel
- ✓ €1.6 billion share buyback
- ✓ Accelerating growth and improving performance across portfolio
- ✓ Good start in fixing Decorative Coatings



### **Decorative Coatings: restructuring paying off**



#### Progressing well on roadmap

- New global organization in place
- Complexity reduction in products and formulations
- Global brand clustering

#### Key contributor to strong H1 2007 Coatings results

- Decorative Coatings revenues up 13%
- Overall Coatings EBITDA improvement of 11%









## STRATEGIC RATIONALE ICI TRANSACTION



### Coatings –attractive industry with strong growth potential

- Attractive industry
  - Strong and stable cash flow
  - Low cyclicality
  - Modest capital expenditure requirements
- Fragmented industry clear signs of consolidation
- High growth potential









#### Coatings industry – average LTM EBITDA margins




















<sup>(1)</sup> Sourced from Euromonitor and Akzo Nobel Internal Sources

<sup>(2)</sup> Sourced from The ChemQuest Group and BB&T Capital Markets



### New combined global market share of 14%








#### Strong growth potential



#### PER HOUSEHOLD SPEND ON PAINTS AND COATINGS





#### **Strong international position in Coatings**



#### **EMEA**

#### **North America**

#### **Emerging Markets**

**Decorative Coatings** 



$$\checkmark\checkmark$$





Industrial **Coatings** 



ICI



ICI



ICI

Relative Market Position @



$$\checkmark\checkmark$$

**Moderate** 



### A perfect strategic fit in Decorative Coatings





- Presence on all continents
- Ability to serve customers worldwide
- Complementary fit across regions, markets and brands
- Well positioned in highly attractive platforms for growth




### Geographic expansion into high growth markets



# Akzo Nobel Decorative Coatings today

Decorative Coatings Revenues in 2006 of €2.3 billion




# ICI's leading Decorative positions in emerging markets

China	#2
India	#3
Indonesia	#2
Malaysia	#1
Pakistan	#1
Thailand	#2
Vietnam	#2
Brazil	#2
Argentina	#1

#### **Pro Forma combined**

Pro forma Decorative Coatings revenues in 2006 of €5.5 billion<sup>(1)</sup>



<sup>(1)</sup> Based on Akzo Nobel's "Coatings" revenues and ICI's "Paints" revenues, applied €/ £ exchange rate of 1.478

<sup>(2)</sup> Sourced from ICI Q2 results 2007



#### **U.S.** decorative market



- Largest (25%) and most attractive coatings market worldwide
- Under pressure since mid-2006
- New home sales account for 25%
- Revised strategy initiated by ICI end of 2006
- Improved margins and profits
- Conservative assumptions made







# KEY ELEMENTS ICI TRANSACTION



#### **Key terms of ICI transaction**



- Offer price of 670p in cash for each ICI share
  - 5p second ordinary interim dividend
  - Transaction financed by the proceeds of OBS sale of €11 billion
- On-sale of part of National Starch to Henkel for €4 billion
- Key financial effects:
  - Earnings enhancing
  - IRR meaningfully above Akzo Nobel's WACC of 8%
  - EVA positive in year 3





#### National Starch strategic review update



#### Specialty Starches:

- Attractive business with H1 2007 revenues of approx. €390 million and an EBITDA margin of 17%
- Intention to seek new owner

#### Specialty Polymers:

- Excellent performance record with continuing growth potential
- H1 2007 Revenues of €205 million and an EBITDA margin of 23%
- Akzo Nobel will retain the business



#### Total synergies have a NPV of approx. €2.5 billion ⊕



# Estimated annual pre-tax cost synergies of €280 million p.a.



# Other synergies with an estimated post-tax NPV of €375 million, of which 75% is cash related

- Opportunities to grow revenues faster
- Reduction in working capital
- Consolidation of manufacturing sites
- Opportunity costs of building position in Asia by Akzo Nobel


85% of annual synergies to be realized in the first three years



#### About 50% of synergies paid away "



- Synergies paid away is a simple way to evaluate attractiveness of deal
- Broker consensus fair value of ICI is approx.515p
- Guidance for trading multiple for Henkel businesses is between 8.0x and 9.0x





### Preparing for fast and effective integration



- Ambition to retain key ICI management
- New top management in place at closing, details to be announced after EGM approvals
- Teams will be in place for fast integration, implementing planned synergies
- Regular updates on implementation progress



#### ICI acquisition - anticipated key milestones







## **AKZO NOBEL: THE TRANSFORMATION**





### Well balanced portfolio



#### **Revenues by segment**

#### Revenues by geo area





<sup>(1)</sup> Revenue of Specialty Starches not included in the figures

<sup>(2) 2006</sup> pro forma figures



#### Strategy going forward



- Accelerate organic growth, leveraging our leading positions
- Be an active consolidator throughout portfolio
- Capture the synergies of the ICI acquisition
- Further improve profitability through operational excellence
- Build a unique industrial brand



#### New Akzo Nobel will be a top performer



- Attractive industry
- Strong portfolio
- Operational excellence
- Synergies

- Outgrow markets
- EBITDA performance to move to upper half of peer group



### Peer group EBITDA performance



Peer Group EBITDA Margins (1)			
	2007	2008	2009
DuPont	19.8%	19.8%	19.6%
Hercules Inc.	18.9%	19.7%	20.6%
BASF AG	18.0%	17.8%	17.0%
PPG Industries Inc.	15.6%	15.5%	15.1%
Dow Chemical Co.	14.2%	13.8%	12.7%
CIBA	14.1%	14.7%	15.2%
Sherwin-Williams Co.	13.9%	13.9%	14.0%
RPM International Inc.	12.8%	12.9%	13.2%
Kansai Paint Co. Ltd.	12.4%	12.6%	13.3%
Valspar Corp.	12.3%	12.7%	n.a.
Kemira Group	11.9%	12.6%	13.1%
Nippon Paint Co.	8.8%	9.3%	9.8%
Arkema Sa	8.4%	9.5%	10.4%
Average	13.9%	14.2%	14.5%
Median	13.9%	13.8%	13.6%
Akzo Nobel (2)	12.7%		

<sup>(1)</sup> Sourced from IBES Estimates and Worldscope as at 04 October, figures calendarised to December year end. Ranked by 2007 EBITDA margin estimates

<sup>(2)</sup> Akzo Nobel pro forma for ICI - H1 2007




years

#### **Akzo Nobel trading valuation versus peers**

Peer group average AV /
 EBITDA multiple of

7.7x over the last 6

 Peer group valuation exhibits relatively low cyclicality





## **NEW FINANCIAL STRATEGY**



### Financial strategy post-2007 transformation



#### Three guiding principles:

- Solid capital structure
- Attractive dividend payout ratio
- Arm's length position for pensions



#### Solid capital structure



- Maintain investment grade rating (single A- to BBB+ range)
  - FFO/adjusted net debt is key ratio
- Drivers
  - Flexibility for growth strategy
  - Avoid over-exposure to volatility of financial markets
  - Continue to deal proactively with pension deficit



#### Attractive dividend payout ratio



#### **Current policy:**

 Dividend pay-out ratio of 35 to 40% of net income before incidentals

#### New dividend policy:

- Minimum of 45% pay-out ratio of net income before incidentals
- 2007 interim dividend proposal
  - Increased from €0.30 per share to €0.40 per share
  - Ex dividend date: October 24, 2007
  - Payment date: October 31, 2007



#### Create arm's length position on pension matters

- Over €2 billion deficit
- Committed to fund deficits over time
- Change to defined contribution (DC) for new entrants
- Ring fence other post retirement obligations



#### Return of additional cash to shareholders



- 2007 share buyback program of €1.6 billion completed
- 2008/2009 capital return program:
  - Share buyback program of €2.0 billion
    - Timing: right after Henkel closing
  - Return of paid in capital of €1.0 billion
    - Timing: after completion of share buyback
  - Both subject to shareholder approval
    - Timing: AGM in April 2008



# SUMMARY



#### **Summary: Transforming Akzo Nobel**



- Delivered on promises over last five years, including TSR of 270%
- ICI acquisition and the on-sale to Henkel will be EVA positive in year 3
- The new-look company will improve EBITDA performance into the upper half of its peer group
- We will maintain a solid investment grade rating, an attractive dividend pay-out ratio of at least 45%, and return up to €3 billion





# **Appendix**





#### **Update on Organon BioSciences sale**

- On March 12, 2007, Akzo Nobel announced its intended sale of Organon BioSciences to Schering-Plough for €11 billion
  - All closing conditions, except certain anti-trust clearances, have now been satisfied
    - Employee consultation process successfully completed early September 2007
    - Related sale and purchase agreement has been signed on September 30, 2007
  - Closing expected by no later than end of 2007 and thus before completion of the transaction with ICI
  - Shering-Plough has secured funding of \$14.9 billion(1) for the acquisition of Organon BioSciences.

At \$1.35:€1 rate, including transaction costs





#### Pre-agreed on-sale with Henkel

- "Adhesives" and "Electronic Materials" businesses.
- Agreed purchase price of €4 billion
- Expected to close 3 -10 months following closing of ICI acquisition
- Conditional only on closing of ICI acquisition and certain mandatory anti-trust clearances (Henkel has to do whatever it can to obtain clearances)
- Estimated break-up costs of €414 million, including tax break-up costs

#### Compelling strategic rationale for all parties

- Focus on businesses that offer most synergies
- Meeting strategic and financial objectives

#### Enabled Akzo Nobel to increase initial offer whilst maintaining its financial discipline

- Implied LTM EBITDA multiple for the retained businesses of 7.8x<sup>(1)</sup>
- Reduction from initial LTM EBITDA multiple for entire business of 8.2x<sup>(2)</sup>
- Generates £2.7 billion of funds (pre break-up costs)

<sup>(1)</sup> Pro forma for full run-rate synergies; excluding break-up costs; before any adjustments for IAS 19 pension deficit



### Industry consolidation – top 10 companies



Rank	1991	2000	2008
1	ICI	Akzo Nobel	Akzo Nobel + ICI
2	<b>BASF Coatings</b>	PPG	PPG + SigmaKalon
3	PPG	ICI	Sherwin Williams
4	Akzo Coatings	Sherwin Williams	<b>DuPont Coatings</b>
5	Sherwin Williams	<b>DuPont Coatings</b>	Valspar
6	Nippon Paint	Valspar	RPM
7	Kansai Paint	<b>BASF Coatings</b>	<b>BASF Coatings</b>
8	Valspar	Nippon Paint	Kansai Paint
9	Courtaulds	Kansai	Nippon Paint
10	Herberts	SigmaKalon	Masco

(1) Source Akzo Nobel







- 2007 capital return program (completed)
  - Share buyback program of €1.6 billion
  - completed end of August 2007
  - Average repurchased price €59.84
  - Cancellation of 26.7 million repurchased common shares planned at end November 2007
  - After cancellation approx. 262 million share outstanding



### Minimum Payout Ratio of 45% Going Forward



Peer Group Dividend Payout Ratios <sup>(1)</sup>	Payout Ratio		
	2005	2006	
Arkema Sa	0%	0%	
BASF AG	35%	47%	
CIBA	98%	77%	
Dow Chemical Co.	28%	39%	
DuPont	70%	43%	
Hercules Inc.	0%	0%	
Kansai Paint Co. Ltd.	21%	23%	
Kemira Group	49%	50%	
Nippon Paint Co.	26%	28%	
PPG Industries Inc.	53%	45%	
RPM International Inc.(2)	(97%)	39%	
Sherwin-Williams Co.	24%	23%	
Valspar Corp.	28%	25%	
Average	26%	34%	
Median	28%	39%	
Akzo Nobel <sup>(3)</sup>	38%	39%	

<sup>(1)</sup> Sourced from Capital IQ – DPS / EPS (excluding exceptionals)

<sup>(2)</sup> In the case of RPM 2006 and 2005 refer to years ending May 2007 and May 2006 respectively

<sup>(3)</sup> Akzo Nobel internal data – Dividend Payout relative to Net Income pre Incidentals







#### Recipients

Neither this document nor any copy of it may be taken or sent to the US, Canada or Japan and may not be distributed, either directly or indirectly, in the US, Canada or Japan or to any resident of these countries.

This communication is directed only at persons who (i) are persons falling within Article 19(2) ("investment professionals") of the Financial Services and Markets Act 2000 (Financial Promotions Order) 2005 (the "Order") having professional experience in matters relating to investments falling within Article 19(5) of the Order; (ii) are outside the United Kingdom; (iii) are persons falling within Article 47(2)(a) or (b) of the Order ("persons in the business of disseminating information"); or (iv) are persons falling within Article 49(2)(a) to (d) of the Order ("high net worth companies etc") (all such persons together being "relevant persons"). This document must not be acted upon or relied on by persons who are not relevant persons.

#### Safe Harbor Statement(1)

This presentation contains statements which address such key issues as Akzo Nobel N.V.'s growth strategy, future financial results, market positions, product development, and product approvals. Such statements should be carefully considered, and it should be understood that many factors could cause forecasted and actual results to differ from these statements. These factors include, but are not limited to, price fluctuations, currency fluctuations, progress of product development, product testing and regulatory approval. developments in raw material and personnel costs, pensions, physical and environmental risks, legal issues, and legislative, fiscal, and other regulatory measures. Stated competitive positions are based on management estimates supported by information provided by specialized external agencies. For a more comprehensive discussion of the risk factors affecting our business please see our Annual Report on Form 20-F filed with the United States Securities and Exchange Commission, a copy of which can be found on the company's corporate website www.akzonobel.com.

#### Disclaimer

In addition, this presentation contains forward-looking statements about Akzo Nobel N.V., Imperial Chemical Industries Plc and their respective subsidiaries and businesses. These include, without limitation, those concerning the strategy of the integrated group, future growth potential of markets and products, profitability in specific great, synergies resulting from a merger between Akzo Nobel N.V. and Imperial Chemical Industries Plc, post-merger integration, the future product portfolio, implications of antitrust laws and regulation, development of and competition in economies and markets of the combined group. These forward looking statements involve known and unknown risks, uncertainties and other factors, many of which are outside of Akzo Nobel N.V.'s control, are difficult to predict and may cause actual results to differ significantly from any future results expressed or implied in the forward-looking statements in this presentation.

While Akzo Nobel N.V. believes that the expectations reflected in this presentation are reasonable, no assurance can be given that such expectations will be correct and no quarantee of whatsoever nature is assumed in this respect. The uncertainties include, amongst others, the risk that Akzo Nobel N.V. will not succeed in acquiring Imperial Chemical Industries Plc or not on the terms assumed in this presentation, the risk that closing conditions may not be satisfied, the business of Imperial Chemical Industries Plc will not be integrated timely and successfully, synergies will not materialize, or a change in general economic conditions, the closing of the agreed on-sale of Adhesives and Electronic Materials to Henkel and government and regulatory actions. These known, unknown and uncertain factors are not exhaustive, and other factors, whether known, unknown or unpredictable, could cause the combined group's actual results to differ materially from those assumed hereinafter. Akzo Nobel N.V. undertakes no obligation to update or revise the forward-looking statements in this presentation whether as a result of new information, future events or otherwise.

Nothing in this document is intended to be, nor shall be interpreted as, a profit forecast. Any statement in this document of estimated cost savings or one-off costs for achieving them. contained in this document relates to future actions and circumstances which, by their nature, involve risks, uncertainties and other factors. Because of this, the cost savings referred to may not be achieved, or those achieved could be materially different from those estimated. Any statement regarding earnings enhancement is not a profit forecast and should not be interpreted to mean that Akzo Nobel's future earnings per share will necessarily match or exceed the historical published earnings per share of Akzo Nobel or ICI. Past performance cannot be relied on as a guide to future performance.